ORACLE: Observation of ResiduAl Cancer with Liquid Biopsy Evaluation
To measure distant recurrence free interval from end of treatment stratified by landmark (4-12 weeks post-treatment) and serial post-treatment ctDNA detection status (detected vs. not detected). The purpose of ORACLE is to demonstrate the ability of a n
Why this Research Matters
This study plans to learn more about if a blood test can predict whether cancer will recur (come back) after initial treatment. In some cases, cancer is cured after initial treatment, but in other cases, cancer cells remain in the body. These remaining c
Who can Participate
- treated with curative intent - planning to undergo regular follow up and monitoring for cancer recurrence per standard of care at the enrolling site patients must have either: - Esophageal or gastroesophageal junction carcinoma (stage II-III) or - Detailed eligibility criteria is available on clinicaltrials.gov. These requirements will be discussed with your doctor and/or study representative. Click the NCT number link below to learn more about this study on ClinicalTrials.gov
Study ID
Protocol Number: 22-0526
More information available at ClinicalTrials.gov: NCT05059444
Meet the Team
Principal Investigator